LSV Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.28M | Hold |
15,500
| – | – | ﹤0.01% | 644 |
|
|
2026
Q1 | $1.19M | Buy |
15,500
+6,700
| +76% | +$523K | ﹤0.01% | 622 |
|
|
2025
Q4 | $695K | Buy |
+8,800
| New | +$762K | ﹤0.01% | 669 |
|
|
2022
Q4 | – | Sell |
-35,300
| Closed | -$1.14M | – | 868 |
|
|
2022
Q3 | $1.14M | Sell |
35,300
-28,700
| -45% | -$982K | ﹤0.01% | 638 |
|
|
2022
Q2 | $1.9M | Sell |
64,000
-2,600
| -4% | -$75K | ﹤0.01% | 613 |
|
|
2022
Q1 | $1.87M | Buy |
66,600
+3,300
| +5% | +$123K | ﹤0.01% | 646 |
|
|
2021
Q4 | $2.92M | Sell |
63,300
-25,400
| -29% | -$1.09M | 0.01% | 602 |
|
|
2021
Q3 | $2.91M | Hold |
88,700
| – | – | 0.01% | 611 |
|
|
2021
Q2 | $3.11M | Buy |
88,700
+2,514
| +3% | +$85.5K | 0.01% | 611 |
|
|
2021
Q1 | $3.11M | Buy |
86,186
+20,886
| +32% | +$654K | 0.01% | 620 |
|
|
2020
Q4 | $1.9M | Sell |
65,300
-900
| -1% | -$25.8K | ﹤0.01% | 681 |
|
|
2020
Q3 | $1.87M | Sell |
66,200
-3,200
| -5% | -$95.3K | ﹤0.01% | 662 |
|
|
2020
Q2 | $2.24M | Sell |
69,400
-2,100
| -3% | -$75.3K | ﹤0.01% | 654 |
|
|
2020
Q1 | $2.91M | Sell |
71,500
-400
| -0.6% | -$21.3K | 0.01% | 578 |
|
|
2019
Q4 | $4.43M | Sell |
71,900
-23,300
| -24% | -$1.54M | 0.01% | 587 |
|
|
2019
Q3 | $6.94M | Sell |
95,200
-18,800
| -16% | -$1.41M | 0.01% | 509 |
|
|
2019
Q2 | $9.37M | Buy |
114,000
+32,215
| +39% | +$2.29M | 0.02% | 481 |
|
|
2019
Q1 | $5.77M | Buy |
81,785
+17,885
| +28% | +$1.05M | 0.01% | 545 |
|
|
2018
Q4 | $2.88M | Sell |
63,900
-231,000
| -78% | -$12.1M | 0.01% | 635 |
|
|
2018
Q3 | $16.7M | Sell |
294,900
-5,500
| -2% | -$337K | 0.02% | 417 |
|
|
2018
Q2 | $20.1M | Sell |
300,400
-5,400
| -2% | -$337K | 0.03% | 380 |
|
|
2018
Q1 | $17.8M | Buy |
305,800
+280,600
| +1,113% | +$17.8M | 0.03% | 402 |
|
|
2017
Q4 | $1.62M | Buy |
25,200
+900
| +4% | +$56K | ﹤0.01% | 747 |
|
|
2017
Q3 | $1.27M | Hold |
24,300
| – | – | ﹤0.01% | 788 |
|
|
2017
Q2 | $1.14M | Hold |
24,300
| – | – | ﹤0.01% | 792 |
|
|
2017
Q1 | $1.2M | Sell |
24,300
-1,900
| -7% | -$107K | ﹤0.01% | 784 |
|
|
2016
Q4 | $1.59M | Buy |
26,200
+10,300
| +65% | +$630K | ﹤0.01% | 743 |
|
|
2016
Q3 | $1.05M | Hold |
15,900
| – | – | ﹤0.01% | 769 |
|
|
2016
Q2 | $887K | Sell |
15,900
-300
| -2% | -$14.6K | ﹤0.01% | 790 |
|
|
2016
Q1 | $545K | Sell |
16,200
-600
| -4% | -$20.4K | ﹤0.01% | 812 |
|
|
2015
Q4 | $758K | Buy |
16,800
+6,600
| +65% | +$284K | ﹤0.01% | 775 |
|
|
2015
Q3 | $403K | Hold |
10,200
| – | – | ﹤0.01% | 824 |
|
|
2015
Q2 | $632K | Buy |
+10,200
| New | +$607K | ﹤0.01% | 765 |
|
Other funds holding ANIP
MMA
PCM
LSV Asset Management's ANIP Position: Q2 2026 in Review
LSV Asset Management held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 15,500 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #644.
LSV Asset Management first reported a position in ANIP in Q2 2015 and has held it in 33 quarters since. The position peaked at $20.1M in Q2 2018. 116 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- LSV Asset Management held 15,500 shares of ANI Pharmaceuticals worth $1.28M as of Q2 2026.
- LSV Asset Management left its ANI Pharmaceuticals share count unchanged in Q2 2026.
- ANI Pharmaceuticals made up ﹤0.01% of LSV Asset Management's portfolio in Q2 2026, its #644 holding.
- LSV Asset Management first reported a position in ANI Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
- LSV Asset Management's ANI Pharmaceuticals position peaked at $20.1M in Q2 2018.
- 116 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.